Listen to the article
0:00
Une enquête menée au centre hospitalier d’Avignon par des médecins et des sociologues du travail auprès de plus de 500 patients touchés par un lymphome conclut à une « sous-estimation massive » des cancers d’origine professionnelle en France.
22 commentaires
The cost guidance is better than expected. If they deliver, the stock could rerate.
Good point. Watching costs and grades closely.
Production mix shifting toward Planète might help margins if metals stay firm.
Good point. Watching costs and grades closely.
Interesting update on « Personne ne nous a jamais mis en garde » : les cancers professionnels, continent inexploré de la santé publique. Curious how the grades will trend next quarter.
Good point. Watching costs and grades closely.
Nice to see insider buying—usually a good signal in this space.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Silver leverage is strong here; beta cuts both ways though.
Production mix shifting toward Planète might help margins if metals stay firm.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Uranium names keep pushing higher—supply still tight into 2026.
Good point. Watching costs and grades closely.
The cost guidance is better than expected. If they deliver, the stock could rerate.
Good point. Watching costs and grades closely.
Silver leverage is strong here; beta cuts both ways though.
Good point. Watching costs and grades closely.
I like the balance sheet here—less leverage than peers.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.